Uncategorized
FDA Approves Vadadustat (Vafseo) for Anemia in Chronic Kidney Disease Patients on Dialysis and Daprodustat (Jesduvroq) for Dialysis-Dependent CKD Adults
Anemia, Chronic Kidney Disease (CKD), Vadadustat (Vafseo), Daprodustat (Jesduvroq), Oral medication, FDA approval, Hemoglobin levels, Black Box Warning, Efficacy and safety data, Post-marketing safety data
#FierceMadness: The Battle for the Best Biotech Names Reaches the Sweet 16
#FierceMadness, Best Biotech Name Tournament, Sweet 16, Bracket Challenge, Fierce Biotech, Creative Branding, Biopharma Industry
Gilead Partners with Xilio Therapeutics for Novel Tumor-Activated IL-12 Program
interleukin-12, Xilio, XTX301, development aspects
Walgreens Takes $6 Billion Hit from VillageMD Investment Amid Strategic Review
Walgreens, VillageMD, Quarter 2, $6 billion loss, Write-down, Investment Value Decline, Strategic Review, Cost Savings Plan, Underperforming Clinics Closure
Gamida Cell Shares Plummet Following Transition to Privately Owned Entity Under Highbridge Capital Management
Gamida Cell, Share Crater, Private Transition, Highbridge Capital Management, Stem Cell Therapy Maker, Restructuring Support Agreement (RSA), Omisirge
Pfizer Continues FDA Approval Expectations for Sickle Cell Disease Therapy Despite Terminating One Phase 3 Trial
Pfizer/ Sickle Cell Disease/ FDA Approval/ Inclacumab/ THRIVE Program/ Monoclonal Antibody/ Terminated Trial/ Poor Accrual
“#FierceMadness 2024: Best Biotech Name Tournament Round of 32 Results”
#FierceMadness, Best Biotech Name Tournament, Round of 32 Results, Drug Names, Marketing Suitability, Mounjaro, Daybue, Beyfortus, Wainua, Fierce Biotech, Voting Results
Pfizer Discontinues Phase III Trial for Sickle Cell Treatment Amid Challenges in Patient Recruitment
Pfizer, Sickle Cell Disease, Phase III Study, Inclacumab, Poor Accrual, Recruitment Challenges, THRIVE Program, ClinicalTrials.gov, Gene Therapies
Praxis’ Mid-Stage Triumph Propels Advancement of Novel Epilepsy Drug
Praxis Precision Medicines, PRAX-628, Functionally Selective Small Molecule, Hyperexcitable State of Sodium Channels, Adult Focal Onset Epilepsy Treatment, Phase IIa Proof of Concept Study Success, Second Half of 2024 Efficacy Study Planned
Groundbreaking Data Revealed for Genetic Epilepsy Drug STK-001 by Stoke Therapeutics, Exhilarating Investors
Stoke Therapeutics, STK-001, Genetic Epilepsy Drug, Dravet Syndrome, Antisense Oligonucleotide, Seizure Reduction, Positive Clinical Trial Data, Investor Enthusiasm